Core Insights - Johnson & Johnson announced that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) significantly reduces the development of EGFR and MET resistance mutations compared to osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) [1][2][3] - The Phase 3 MARIPOSA study indicates that this combination therapy not only extends overall survival but also changes the disease biology by preventing acquired resistance, with projected overall survival exceeding four years [1][3][4] Company Insights - Johnson & Johnson's RYBREVANT plus LAZCLUZE is approved in the U.S., Europe, and other markets for first-line treatment of patients with EGFR-mutated NSCLC based on the Phase 3 MARIPOSA study [5][9] - The MARIPOSA study enrolled 1,074 patients and is a randomized Phase 3 trial evaluating the efficacy of RYBREVANT in combination with LAZCLUZE versus osimertinib and LAZCLUZE alone [6][7] Industry Insights - Resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) like osimertinib remains a significant barrier to long-term disease control, highlighting the need for next-generation strategies [2] - The study results suggest that TKI monotherapy is insufficient for first-line treatment of EGFR-mutated lung cancer, indicating a shift towards combination therapies [3][4]